Blueprint Medicines is committed to leveraging the power of our drug discovery platform to deliver transformative, targeted medicines to a broad spectrum of patients with genomically defined diseases driven by the abnormal activation of kinases.

Our platform spans a wide range of disease areas. While we may expand into other disease areas in the future, our current focus is on genomically defined cancers, which enables a cost-efficient discovery and development strategy.

In March 2016, we announced a worldwide collaboration with Roche to accelerate and expand the discovery, development, and commercialization of up to five small molecule therapeutics targeting kinases believed to be important in cancer immunotherapy.

In June 2018, we announced an exclusive collaboration and license agreement with CStone Pharmaceuticals to develop and commercial avapritinib, BLU-554 and BLU-667 in Greater China. CStone Pharmaceuticals has exclusive rights to develop and commercialize the licensed products either as monotherapies or combination therapies in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains all rights in the rest of the world.

We will continue to evaluate collaborations to maximize the value of our programs, allowing us to expand our geographic reach or leverage the expertise of strategic partners.

For partnering inquiries, please contact